Enveric Biosciences
ENVB
0 hedge funds and large institutions have $20K invested in Enveric Biosciences in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
2.29% less ownership
Funds ownership: 2.31% → 0.02% (-2.3%)
78% less capital invested
Capital invested by funds: $90K → $20K (-$70K)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$70K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2K |
ENVB Hedge Fund Activity: Q3 2020 in Review
0 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q3 2020, worth a combined $20K — down 78% from $90K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ENVB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Virtu Financial, exiting entirely with an estimated $70K sold.
- 0 institutional investors held Enveric Biosciences (ENVB) as of Q3 2020, down from 1 in Q2 2020.
- Funds reported $20K of Enveric Biosciences stock for Q3 2020, down 78% quarter-over-quarter.
- 0 funds opened new Enveric Biosciences positions in Q3 2020 and 1 closed out, a net change of -1 holder.
- The largest Enveric Biosciences seller in Q3 2020 was Virtu Financial, an estimated $70K sold.
Based on aggregated 13F filings for Q3 2020.